



Big  Idea  
CONNECTpreneur

# Virtual Rocket Pitch + Power Networking

*May 29, 2025 | 11am - 12:30pm EDT*

***Join Us At***

***The World's LARGEST  
investor pitch event***

CONNECTPRENEUR.ORG



# AGENDA

**11:00 - 11:05 AM**

## VIRTUAL NETWORKING

**11:05 - 11:15 AM**

## WELCOME & INTRODUCTIONS

- TIEN WONG, Founder and Host, CONNECTpreneur Community
- AVERY NORTH, Assistant Community Manager, CONNECTpreneur

**11:15 - 12:00 PM**

## ROCKET PITCH SESSION

Companies will be introduced by:

- SARA CLASPER, Associate Attorney, NEXT powered by Shulman Rogers
- DEBBIE CLINE, Founder and Chief of Customer Success, Buzzy Rocket

**12:00 - 12:30 PM**

## PRESENTING COMPANY BREAKOUT ROOMS & VIRTUAL NETWORKING

# PRESENTING COMPANIES



**FindMyClinicalTrial Inc.**- Killian Lozach



**Kool Shades LLC** - Mickey Loeb



**Sen-Jam Pharmaceutical** - Christine Leonard



**SunRay Scientific Inc.** - Madhu Stemmermann



**Think Now, Inc.** - Greg Simpson



**Ziab** - Aron Rachamim

# SPEAKERS



## **TIEN WONG, CEO, OPUS8, INC. @tienwong**

Tien is CEO of Opus8, an investment and advisory firm which helps technology companies and alternative investment fund managers raise capital. He is also Chairman of Lumious, a leader in corporate tech training and learning analytics, as well as Chairman of Lore Systems, a provider of network engineering, cloud computing, and strategic IT consulting.

In 1991, Tien co-founded and served as CEO of CyberRep, Inc. until its acquisition in 2003 by Affiliated Computer Services. CyberRep was one of the largest CRM outsourcing companies in the world with over 2,300 employees and \$80 million in revenue. Today, the CyberRep/ACS business unit is one of the world's largest call center operations, with nearly \$3 billion in revenue as divisions of Xerox, Conduent, and Continuum. CyberRep was ranked for 4 consecutive years in INC. Magazine's "Inc. 500" as one of the fastest-growing companies in the USA. CyberRep was profitable for 11 straight years and was backed by Allied Capital Corporation.

Tien is a recognized international expert in CRM, direct marketing, and BPO, having presented at dozens of industry events around the world on CRM and BPO topics. He has provided industry commentary on the ABC, Fox, NBC, CNBC, Maryland Public Television, and China's CCTV networks, as well as Time Magazine, The Washington Post, Inc. Magazine, and Success Magazine. He serves on several boards including the Montgomery County (MD) Economic Development Corp., Center for Innovation Technology GAP Fund's Investment Advisory Board, Junior Achievement, and Refraction. He was appointed by Governor Martin O'Malley to the 9-member Maryland Venture Fund Authority which allocates and manages over \$130 million of capital which is invested into top-tier venture funds and startups. He is an Entrepreneur in Residence at Georgetown University's McDonough School of Business, and a graduate of Dartmouth College.



## **SKYLAR RALLISON, COMMUNITY MANAGER, CONNECTPRENEUR**

Skylar Rallison is a dynamic professional who wears multiple hats as the Community Manager for CONNECTpreneur and Business Analyst for Opus8. She graduated from The Marriott School of Business at Brigham Young University with a degree in Entrepreneurial Management. She has many years of experience in Business Management, Social Media Marketing/Management, Data Analytics, Business Leadership, and Project Management. With a diverse skill set and a passion for facilitating connections and driving business growth, Skylar thrives in the intersection of Community Management and Strategic Analysis.

Skylar enjoys her current role at CONNECTpreneur, which hosts the world's largest monthly investor pitch events as well as 1/2-day Forums with upwards of 900 RSVPs, featuring VIP guests, speakers, exciting presenting companies, and the best CXO to CXO networking on the East Coast. Skylar is pivotal in fostering engagement and building relationships within the investor and entrepreneur community. She creates inclusive digital spaces where members can share insights, collaborate on opportunities, and build a supportive network. Her role includes but is not limited to, team management, event coordination, project management, and marketing.

She also enjoys her current role as a business analyst at Opus8. Opus8 assists companies and fund managers (private equity, VC, and hedge funds) raise private capital from family offices, UHNW individuals, and institutions. Skylar leverages her analytical mindset and attention to detail to provide valuable insights for Opus8. Through her meticulous analysis of investment opportunities and industry research, Skylar helps drive informed decision-making, enabling Opus8 to curate high-quality events that bring together investors and promising ventures.

## FindMyClinicalTrial Inc.

**FindMyClinicalTrial Inc. connects underrepresented patients with clinical research opportunities through a first-in-class AI-driven platform that empowers biopharmaceutical companies to promote trials and optimize enrollment.**

**Company Background:** Established in August of 2023, the FindMyClinicalTrial patient engagement platform was created out of desperate need to reach underrepresented patients looking for clinical research opportunities.

**Leadership Team:** Leadership Team: Killian Lozach CEO, Javad Rajabi CTO, Genevieve Satzinger SVP, Emma Briggs VP, and Monte Chetkof VP.

**BOD and Scientific Advisor:** Gavin Clingham, JD, Lindsay Videnieks, JD, Jasmine Patel, MPH, Sunny Dandapantula, Amaal Starling, MD, Laure Escoubet, PhD, Stephane Richard, PhD.

Combined 145+ years of experience across clinical development, biopharma research, pharmaceutical consulting & business development, and patient & provider engagement.

**Products/Services:** FindMyClinicalTrial offers biopharmaceutical companies clinical trial promotion opportunities on our web-app platform of engaged patients, providers, and families.

**Technologies/Special Know-How:** FindMyClinicalTrial offers a first-in-class clinical trial search engine platform that allows patients, families, and providers to search, share, save, and enroll in clinical trials.

Through our Mayo Clinic collaboration, we have perfected trial engagement and promotion to a science with a patient-centered approach utilizing AI and machine learning to optimize interaction and enrollment.

**Market:** FindMyClinicalTrial's target customer segment are biopharmaceutical companies actively running clinical trials.

FindMyClinicalTrial seeks to bridge the gap between the 15 million patients looking for clinical trials and the 23,000+ ongoing trials in the United States.

**Distribution Channels:** Our platform is commercially available on the web, app store, google play store, and our executive team has deep-rooted connections with biopharmaceutical partners, advocacy organizations, and research hospitals.

### Quick Facts

**Company Name:**  
FindMyClinicalTrial Inc.

**Contact:** Killian Lozach,  
President, CEO, & Founder

**Address:** 20 Ridge Square NW,  
Apt 633 Washington DC

**Phone:** (858) 336 5157

**Email:**  
killian.lozach@findmyclinicaltrial.org

**Website:** findmyclinicaltrial.org

**Industry:** Digital Health / Clinical  
Trial Recruitment

**Bank:** Coastal Community Bank  
(Bluevine)

**Number of Employees:** 5 Full and  
Part-Time

**Leadership Team:** Killian Lozach,  
Javad Rajabi, Genevieve Satzinger,  
and Emma Briggs

**Amount of Financing Sought:**  
\$700,000 USD

**Current Investors:** 6 Investors

**Competition:** Companies such as Antidote, AutoCruitment, and BBK Worldwide focus on selling patient email lists to site investigators and biopharmaceutical companies while FindMyClinicalTrial partners with industry in promoting trials to engaged patients. FindMyClinicalTrial can reach underrepresented populations through monthly promotions on our platform to "best fit" patients in targeted locations. We build trust and engagement, rather than sell an email list with low turnover rates.

### Financial Projections (Unaudited):

	2025	2026	2027	2028
Revenue	\$15,000	\$360,000	\$720,000	\$1,200,000
EBIT (dollars in thousands)	\$ - 285,000	\$ - 240,000	\$70,000	\$500,000





## Executive Summary

# First-to-market paper-framed UV400 sunglasses

kool-shades.com

## Company Overview

Kool Shades LLC is a stylish, sustainable kids' wearables brand at the intersection of fashion, wellness, and innovation. Our UV-protective sunglasses are fun, durable, and customizable—helping kids stay safe while providing brands and pediatric providers with a creative, non-screen way to connect with Gen Alpha.

## The Problem

- **UV Vulnerability** – Children receive 3x more UV exposure than adults but lack consistent eye protection.
- **Loss & Waste** – Kids frequently lose or break sunglasses, with many ending up in landfills
- **Brand Disconnect** – Brands and healthcare providers lack fresh, effective ways to engage with young families.

## Proven Product

Our enterprise has generated \$1.5 million in gross sales of eye-protection products. We are ready to scale quickly!



## Our Solution

Kool Shades offers trendy, eco-conscious eyewear that kids love to wear—doubling as branded wellness tools for advertisers, optometrists, and schools. Each pair is both protection and promotion.



## 5-YEAR FINANCIAL PROJECTION

Year	Revenue	EBITDA
2025	\$850K	\$75K
2026	\$4M	\$600K
2027	\$9M	\$2M
2028	\$18M	\$5M
2029	\$35.9M	\$11.5M

## Raising \$850,000

*We're open to discussing investment terms.*

## Contact

Mickey Loeb, Founder  
mickey@kool-shades.com  
480-421-6646

## WE DON'T DO SICK-CARE. WE END IT.

*Upstream revolutionary anti-inflammatories that work with the body, not against it.*

**Overview:** Sen-Jam Pharmaceutical is a clinical-stage company pioneering PAIR™—a dual-mechanism platform that repurposes two decades-proven small molecules to calm mast-cell-driven inflammation before tissue damage or disease denigration begins. This single, preemptive, upstream approach powers an 11-asset pipeline spanning eight large unmet therapeutic need areas from OTC metabolic-recovery products to hospital-grade critical-care rescue, aiming to turn trillion-dollar disease burdens into rapid, affordable relief.

### The \$1.5 Trillion Inflammatory Problem — (Across Our Four Lead Assets Alone)

Burden	Annual Global Cost	Why Existing Drugs Fall Short
Metabolic overload (food, alcohol, obesity)	<b>\$4.3 T</b>	Treat after damage; cause GI side-effects
Opioid crisis (withdrawal, dependence)	<b>\$2.7 T</b> U.S. alone	Relies on substituting one opioid for another
Respiratory infections (URIs, COPD, COVID)	3rd-leading killer worldwide	Focus on antivirals; ignore inflammatory damage
Runaway hospital inflammation (sepsis/ARDS)	<b>11 M deaths</b>	Biologics arrive too late, cost too much

### The PAIR™ Platform

- **Two proven small molecules** (NSAID + mast-cell modulator) repurposed in new ratios.
- **Pleiotropic impact:** calms mast cells *and* COX-1 and COX-2 at once → stops inflammation upstream.
- **Oral & IV forms:** low COGS, rapid global scale, OTC and Rx paths.
- **Pipeline of 11 unique assets** across **8 therapeutic areas** with a **TAM of \$400B+**

Stage	OTC Track	Rx Track
<b>Phase 2</b>	<b>SJP-001 Metabolic Recovery</b>	<b>SJP-002C URI Defense</b>
<b>IND-ready</b>	SJP-002 Common Cold	<b>SJP-005 Withdrawal Relief</b>
<b>Pre-clinical</b>	—	<b>SJP-100 Critical-Care Rescue</b> , Opioid Dependence, Opioid Tolerance, Arthritis, Vaccine Side-Effect Relief, Anti-Aging

### Traction & Validation

- **Leadership with over \$730M in successful exists** include academic alliances/Scientific Advisory expertise: Duke University, Harvard, MIT, Memorial Sloan Kettering, Mayo Clinic
- **Expedited FDA Pathway** – 505(b)(2) approach leveraging existing safety data, reducing cost & time to market.
- **Validated Consumer & Market Demand** – Positioned at the intersection of metabolic health, wellness, and preventative medicine.
- **First-Mover Advantage** – No FDA-approved alternative exists, making assets category-defining.
- **Global IP & Manufacturing Readiness** – 60+ patents worldwide, with KVK-Tech partnership ensuring scalable production, FDA ready engineered batches & cost efficiency.
- **Independent Market Validation** – Destum Partners' valuation analysis confirms strong revenue potential and market positioning.

## JOIN THE UPSTREAM REVOLUTION



**Advanced Electronic Materials Manufacturer**  
*Flexible Electronics Begins with Us.*



## Problem

The world needs wearable, flexible, smart technology, but conventional circuit boards and the process to make them are not suitable for the flexible electronics of the future.

## Solution

SunRay has developed next generation conductive adhesives that displace conventional circuitry so flexible electronics can be smaller, lighter, durable, and produced cost-effectively with greener technology.

## Revenue Channels

SunRay generates revenue from material sales, licensing, engineering services, and federal grants. Established partnerships with Henkel and Molex provide access to sales channels and customers across industries, building a strong commercial pipeline of end-user products.

## Competitive Advantage

SunRay's commercial-ready, scalable solution is superior to alternatives and is available now. Eight product/process patents, time in R&D/commercial testing and scalability protect SunRay's position in the marketplace. This has led to opportunities from suppliers and competitors for market partnerships, technology licensing, and M&A.

**Stage:** Production & commercial scale ready with \$55M ARR commercial pipeline

**Market Size:** TAM – \$41B

**Opportunity:** \$3.5M SAFE, \$25M Post Money Cap, 20% discount \$2.3M Committed

**Use of Funds:** Commercialization scale-up: hire personnel, purchase equipment, materials

**Financials:** \$5M raised; and \$11M non-dilutive grant funding. 12- month runway. Cash positive in 2026. \$3M revenue projected in 2025.

**IP:** 8 global patents issued and 8 pending.

## Market

Flexible Electronics and across multiple industries (potential ARR).



Healthcare & Medical  
Devices (\$18M)



Defense/ Aerospace  
Wearables (\$4M)



Consumer Electronics  
Semiconductor (\$15M)



Automotive  
(\$18M)

## Traction

- 22 commercial programs generating revenue now, 32 current opportunities, 50+ total in pipeline
- Officially qualified by Molex, F500
- 15 near-term commercial launch opportunities; \$55M ARR active pipeline
- Continuous glucose monitor expected launch in 2026 with over \$4M potential ARR

## Investors/Advisors

Our Investor-Advisors are made up of tech-focused VC's, serial entrepreneurs with backgrounds in engineering and manufacturing, and former scientists from NASA, Bell Labs, and RIT.



## Snapshot

- Pioneering Drug-free Therapeutic for Adult ADHD
- Product validated in large Clinical Trial (UCLA, UCB)
- Highly experienced team
- Pre-Revenue

## Funding

- \$7.2 NIH Grants (non-dilutive)
- \$2.5M SAFEs for seed capital
- 60% subscribed; \$1M available

## Management Team

### Brett DeSchepper

CEO  
Founder & CEO iHomefinder  
(acq Frontsteps)  
UC Berkeley, PhD Cog Neurosci  
Rensselaer (RPI), BS

### Gregory V. Simpson

CSO/Co-Founder  
Director UCSF Dynamic  
Neuroimaging Lab  
UC Berkeley, PhD Neuropsych  
UCSD, BS

### Brian Cowley

VP, Bus Development  
CEO, Compare Networks  
CEO, President & Board  
Member, AdInfuse  
Bryant Univ, BS

### Evan Hirsch

Chief Product/Experience  
CEO, PlayNice Interactive  
Creative Director, Engine Co.4  
RIT, BFA

### Kathryn Rose

CFO  
Serial Startup CFO/COO  
UC Berkeley, MBA Finance  
UT Austin, BA

## Think Now, Inc.

www.think-now.com  
[brett@think-now.com](mailto:brett@think-now.com)  
[greg@think-now.com](mailto:greg@think-now.com)

## Adult ADHD is a Massive Underserved Market

1.1B adults worldwide struggle with ADHD and attention impairments. Drugs are the only therapeutics that directly improve attention dysfunction. However, only 13% take the drugs. Imagine there was a non-drug therapeutic for ADHD to help almost a billion people globally.

## Pioneering Drug-free Therapeutic for Adult ADHD

The NIH awarded ThinkNow 5 successive grants totaling \$7.2M to develop and prove a digital solution for Adult ADHD. ThinkNow's team of world-class cognitive neuroscientists and entrepreneurs built an entirely new type of therapeutic method for ADHD, deploying proprietary Meta-Attention technology.

This digital therapeutic, called Attentio, is a unique evidence-based product that helps adults improve ADHD and perform better:

- The only product that builds skills to increase attention.
- Provides immediate and long-term benefits
- Protected by 4 patents, 2 pending
- Clinically validated at UCLA & UC Berkeley
- Accessible, scalable, low-cost solution

## Three-Phase Launch Plan

The go-to-market strategy targets the \$5B market potential with a 3 phase approach:

- 1) Soft launch OTC product in Q3 2025 enables us to optimize product-market fit and validate marketing strategy while developing distribution channel partnerships.
- 2) With a Series A warchest to capture market share, we will accelerate product distribution in Q4 2026 to help millions of adults with ADHD.
- 3) With Series B funds, we will expand into international markets in 2027.

We will also extend our core IP into the adjacent markets of anxiety and depression.

## Competitive Landscape

The only proven therapeutic that actually improves core attention deficits is medication.

Attentio is the alternative to drugs.

Other solutions touted for ADHD do not actually improve attention dysfunction. They are work-arounds, such as list-making software or organizational tips, or therapy to help cope with anxiety and low self-esteem caused by ADHD.

## Current Status and Opportunity

We are completing a \$2.5M SAFE raise (\$1.5M already raised), which builds on our non-dilutive \$7.2M NIH grants, to fund marketing and operational resources needed to achieve our first commercial milestones. These commercial proof points will allow us to raise a competitive Series A to capture the OTC market.

Our exit strategy is likely through a strategic acquisition by a well-funded player in digital health or pharmaceuticals targeting this very lucrative opportunity.



## REVOLUTIONIZING ANTIBODY DEVELOPMENT

**We disrupt the \$3.7B research antibody market with AI  
– building antibodies 10X smaller, 10X faster, 10X cheaper**

### THE PROBLEM & OPPORTUNITY

Antibodies – essential molecular tools for medical research – are still produced using 1970s methods: injecting animals, waiting months, and laborious screening. This approach costs \$50,000+, takes 6-8 months, and fails 60% of the time, directly blocking scientific progress. Breakthrough advances in computational protein modeling have converged with surging antibody demand, creating the ideal moment for AI disruption in this \$3.7B market.

### OUR SOLUTION: AI REPLACES ANIMALS

Our AI platform generates nanobodies – smaller, more stable antibody fragments – completely without animals. We deliver results 10X faster (days vs. months), 10X cheaper (\$500-5,000 vs. \$50,000+), with higher success rates and the ability to hit previously impossible targets. We provide standardized vials (100µg, \$500-1,000) of application-validated nanobodies that solve researchers' critical pain points. Our direct-from-DNA approach ensures batch-to-batch consistency – eliminating a top complaint from antibody users – while generating 80% gross margins with minimal capital requirements.

### UNIQUE MARKET POSITION & DATA MOAT

While AI antibody companies chase therapeutics requiring years of clinical trials and traditional research antibody companies remain technological dinosaurs, we stand alone as the only AI-native player targeting the \$3.7B research antibody market. Our approach generates thousands of antibodies annually versus competitors' dozens, building up an insurmountable data advantage. We launch quickly in an unregulated market and accelerate through a powerful flywheel: more products create more data, improving our AI, enabling more products and accelerating sales. Research antibody companies can't match our technology, therapeutic companies can't match our data volumes.

### TRACTION & MARKET STRATEGY

We've secured exclusive AI protein modeling technology from Georgia Tech and optimized automated production protocols for launch in Q3 2025. Our strategic roadmap begins with the **huge unmet need** in the 25% CAGR \$307.5M Nanobody Market (2025), expands to disrupt the \$3.7B Research Antibody Market (2026-2027), and ultimately transforms the \$293.6B Diagnostic & Therapeutic Markets (2027+) through strategic partnerships.

### WORLD-CLASS TEAM

Dr. Aron Rachamim, CEO (Cambridge PhD, 15+ years in life science startups, raised \$20M+) leads execution. Professor Jeff Skolnick, Chief Scientist (Georgia Tech Regents' Professor, pioneer of Odijk-Skolnick-Fixman theory, 30+ years in computational biology) is one of the world's foremost authorities in computational protein design. His AI models outperform DeepMind's AlphaFold 2. Jared Slosberg (serial entrepreneur, 100+ tech investments) and Monica Landers (founder of multiple AI startups) complete our leadership. We are advised by industry heavyweights from Abcam and Antibodies-online and distinguished scientists.

### THE BACKBONE OF MODERN LIFE SCIENCES

Ziab isn't just building better antibodies – we're redefining their creation. While recent transactions (Abcam: \$5.7B, BioLegend: \$5.25B) demonstrate market value, they drastically undervalue our potential as we become the technological foundation of modern life sciences through our self-reinforcing system of continuous improvement.

**Contact:** Dr. Aron Rachamim, CEO | **Email:** aron@ziab.com




# PARTNERS



## **NEXT powered by SHULMAN ROGERS**

NEXT disrupts the legacy legal industry by offering a broad range of fixed fee solutions (stand-alone products and annual legal plans) delivered by senior attorneys with valuable business expertise. NEXT solves the problem that startup and emerging growth companies face when launching their business as well as scaling: lack of access to predictable legal fees, seasoned attorneys, the latest technology and key business services. We use cutting edge technology platforms to deliver real efficiencies, transparency and a collaborative environment for clients, attorneys and investors. NEXT partners with its clients to de-risk their business and get to the NEXT level, together reaching each milestone of success. NEXT is powered by Shulman Rogers, a full-service law firm with nearly 100 attorneys offering superior service across a wide range of practice areas. The firm also offers robust personal services such as residential closings and trust and estate planning. Shulman Rogers has earned its reputation for providing quality representation, business insight and client value, serving as a highly attractive alternative to larger, higher-priced firms and smaller, less diverse firms. Learn more at [ShulmanRogers.com](http://ShulmanRogers.com).



## **ANTHONY MILLIN, NEXT CHAIR & PARTNER, SHULMAN, ROGERS**

Anthony Millin is the Chair of NEXT and a trusted legal and business advisor to startup, early-stage, and emerging growth companies. As a corporate and securities attorney, a successful serial entrepreneur, and a venture capitalist, Anthony brings a unique legal and business perspective to advising his clients. Anthony understands firsthand what it takes to start, scale and manage a company, to successfully prepare for and run a fund-raising process, and to address the legal issues faced by a startup. Another specialized skill set Anthony brings to the table is his China-based experience, assisting early-stage and middle-market companies interested in conducting business in China or seeking direct foreign investment from China. Anthony also serves as a Venture Partner at Urban Us, a seed-stage VC firm. Contact Anthony at [amillin@shulmanrogers.com](mailto:amillin@shulmanrogers.com).




## **AEG @enterprisegrowth**

AEG is a values-based membership organization that creates personal and business growth through trusted relationships. As a "Time Machine" for business leaders, AEG accelerates trust and facilitates peer relationships to drive business development and personal growth. We connect three communities of midmarket CEOs, elite business advisors, and regional centers of influence. Through regular programs, education and community facilitation, AEG cultivates deep personal and business relationships, enabling fast, impactful connections, collaboration, and personal and business referrals.



## **MARK HAAS, CEO, AEG @MarkHaas**

Mark Haas is Co-founder and CEO of AEG (Association for Enterprise Growth), responsible for strategy, operations, and expansion of its communities to 30 cities nationally. He was previously President of ROM a strategy and operations management consulting firm, advising CEOs and boards to include leadership training for Tanzanian energy executives, developing curricula to train consultants in 40 countries for an international bank, crafting strategy and innovative business models for \$120 million nonprofit, merging two scientific associations, re-organizing a biomedical research agency, facilitating development of WWIV military strategy, and of facilitating a global R&D strategy for the US Navy.



## **MODUS CREATE @ModusCreate**

We built our company with an ethos of open source, recruiting and retaining the best individual contributors, regardless of location. We are thought leaders who share what we learn and help steer the direction of our open source communities of practice.

We're not just dreamers or doers; we're partners and teachers. We help you instill a culture of learning, innovation, and unlocked potential throughout your organization.

In short, we help you transform your products, platforms, and processes to facilitate organisation-wide digital transformation.



# PARTNERS



## **PAT SHERIDAN, CO-FOUNDER & MANAGING PARTNER, MODUS CREATE**

Pat is focused on the intersection of design, technology, and business. He saw the need for a high-end product consulting firm built with open-source team design and the concept for Modus was born. Pat helps clients see new ways to tackle challenges with emerging technology and brings his unmatched passion to work every day. As a serial entrepreneur and active startup mentor, he's a co-organizer of NoVa.JS and NYC.JS. He is a 2011 graduate of Mind Share, received his MBA from Georgetown University, where he is currently an Entrepreneur-in-Residence, and holds a BFA from the Corcoran College of Art and Design, where he currently serves as an advisory council member for the George Washington University Columbian College of Arts and Sciences.



## **REFRACTION @refractionpt**

Refraction is a leading nonprofit innovation hub in Northern Virginia, that provides mentoring, programs, and office space for startups and high-growth companies to help create jobs in the greater Washington region. In five years, more than 300 member companies have collectively raised over \$350 million in capital. Refraction's partners include Amazon, Cox, Dominion Energy, MITRE, Fairfax County, Arlington County, Loudoun County, Virginia Innovation Partnership Corporation, and Virginia Tech.



## **DINGMAN CENTER FOR ENTREPRENEURSHIP, UNIVERSITY OF MARYLAND @UMD\_Dingman**

The Dingman Center for Entrepreneurship is a top-tier entrepreneurial institute recognized around the world as a leader in enterprise creation. The Dingman Center is continuously pushing the boundaries of teaching and learning with its focus on practical entrepreneurship, global innovation, and international classroom experiences. The Center promotes opportunities that provide maximum resources to start-up businesses in terms of ideation, execution, and financing; and that support its mission to take entrepreneurs "from the back of a napkin to the first \$1 million in financing."



## **KEIRETSU FORUM @KeiretsuAngels**

Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists, and corporate/institutional investors. Keiretsu Forum was founded in the San Francisco East Bay in California in 2000 by Randy Williams. Keiretsu Forum is a worldwide network of capital, resources, and deal flow with 53 chapters on 3 continents. Keiretsu Forum members invest in high-quality, diverse investment opportunities.



## **FITCI - FREDERICK INNOVATIVE TECHNOLOGY CENTER, INC @FITCInc**

The Frederick Innovative Technology Center, Inc. (FITCI) is a business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland. FITCI specializes in the strategic business support of local entrepreneurs in the early stages of mostly science and technology-based businesses: Biotechnology, Information Technology, Renewable Energy, and Cyber Security. FITCI currently has two locations in Frederick, MD, and 52 client companies.



## **THE BALTIMORE ANGELS @baltimoreangels**

The Baltimore Angels is an angel investor group based in Baltimore, MD. Founded in 2009, its mission is to invest profitably in the regional entrepreneurial ecosystem and advance early-stage innovators to the next stage of capital formation. Its vision is to be the most trusted resource for angel capital investment and entrepreneurial mentorship in the Greater Baltimore region. A new generation of angel investing comes to Baltimore. If you are a tech entrepreneur or community-minded investor, please be in touch with Baltimore Angels. This is not your father's (or your uncle's) investment group.

# PARTNERS



## MARYLAND TECH COUNCIL VENTURE MENTORING SERVICES

The Maryland Tech Council Venture Mentoring Services (MTC VMS) program is one of the leading team mentoring services available in the state of Maryland that is both highly sophisticated and results-driven. It exists to foster an environment that encourages innovation while expanding financial and business opportunities for tech, cyber, and life science start-ups. The MTC VMS Program provides free team-based mentoring services to qualified Maryland-based tech and life science venture CEOs who are accepted into the program. Since the MTC VMS program began, more than 75 ventures have enrolled & \$100MM has been raised in capital & grants.



## STARTUP GRIND-COLUMBIA, MD @StartupGrindDC

Startup Grind-Columbia, mid-Maryland Chapter is part of the largest global community for innovation, entrepreneurship, and the startup community. We're actively educating, inspiring, and connecting more than 2MM+entrepreneurs, 600+ cities, and 130+ countries. We nurture startup ecosystems through mentorship, advisory services, education, inspiration, access to capital, and most importantly, connecting members with the resources we need to have the best opportunity to grow phenomenally successful ventures.



## ANGELS + LIFE.SCI INVESTORS

Formed in 1996, the Angels + Life.Sci Investors Network is organized under NJAngels.net. We are a manager-led, loosely organized network of investors and accredited Angels, Coaches, and Experts who Sponsor world-class Entrepreneurs. Our colleagues have deep experience and technical domain expertise in all of the life sciences disciplines in which we are involved, including nanobio tools, materials, and devices: tele-diagnostics, augmented healthcare & remote patient monitoring, automation and robotics, & advanced chemistry for drug discovery.



## GEORGETOWN ENTREPRENEURSHIP INITIATIVE

Entrepreneurship is one of the world's most powerful forces for positive change. Georgetown Entrepreneurship seeks to instill an entrepreneurial mindset in students, foster an entrepreneurial culture across the university, support the successful growth of alumni ventures, and leverage the power of entrepreneurship to make an impact in the world beyond Georgetown.



## JEFF REID, FOUNDING DIRECTOR, GEORGETOWN ENTREPRENEURSHIP INITIATIVE, GEORGETOWN UNIVERSITY'S MCDONOUGH SCHOOL OF BUSINESS @Hoyapreneur

Jeff Reid is the Founding Director of the Georgetown Entrepreneurship Initiative and Professor of the Practice of Entrepreneurship at Georgetown University's McDonough School of Business. Reid is a catalyst for entrepreneurship and a well-known leader in entrepreneurship education. In 2009, Reid launched the Georgetown Entrepreneurship Initiative to catalyze entrepreneurial thinking and activities across Georgetown University and impact the growing DMV startup community.



## RYAN & WETMORE, P.C. @RyanWetmorePC

Ryan & Wetmore is a full-service accounting and management consulting firm, servicing the Northeast/ Mid-Atlantic region since 1988. What makes us different from other accounting firms is our proactive approach. We work hard to earn our clients' confidence by encouraging open communication year-round. This approach has enabled us to help clients become more efficient, more competitive, and more profitable. Through our numerous management engagements, we have become trusted, unbiased advisors.

# PARTNERS



## **PETE RYAN, CO-FOUNDER & PARTNER, RYAN & WETMORE**

Pete co-founded Ryan & Wetmore in 1988, a 3 office, 35-person firm serving the Mid-Atlantic region. He currently works with clients to address tax, audit, and accounting issues. He also has significant experience in international tax matters and business consulting services. His expertise extends to Healthcare organizations, Construction and Real Estate, Government contractors, Technology, Manufacturing, and High Net Worth Individuals. Pete has served on the Board of Directors for several organizations. He is an active member of the Healthcare Advisors Association, the Real Estate and Construction Association, the CPA Manufacturing Services Association, the Virginia Transportation Construction Alliance, and the Construction Financial Management Association.



## **ENTERPRISE TRANSFORMATION SOLUTIONS**

### **INES LEBOW, FOUNDER AND PRINCIPAL @ilebow1**

Ines LeBow is the Founder and Principal Startup Consultant at Enterprise Transformation Solutions (ETS), which advises entrepreneurs on how to position themselves for funding. Over the course of her 30+ years in the industry, Ines has helped companies secure more than \$800M in funding, led start-ups and turnarounds for companies with up to \$500M in revenue, managed 11 M&A transactions, and guided 9 companies to a successful exit. With expertise spanning Operations, Executive Leadership, and Mentoring, Turnarounds, Revenue implementation, Engineering, as well as Communications, Ines has helped many companies prepare for VC and angel investment.





# THANK YOU TO OUR PREP TEAM



**MICHAEL HANSON**  
Consultant  
Optimum Dynamics LLC



**LAURA HILL**  
Chief of Staff  
Bentley



**INES LEBOW**  
CEO  
Enterprise Transformation  
Solutions



**MARISSA LEVIN**  
CEO  
Successful Culture  
International



**JET LU**  
Customer Solutions  
Amazon Web Services



**JACKIE LUO**  
Founder  
BAM Advisory



**MICHELLE MILLER**  
Founder  
MRM Consulting




**JOHN MORGAN**  
General Partner  
Morgan Global



**EVAN SHUBIN**  
Pres. and Founder  
Results.now, Inc. and  
Candlelight Partners



**MALI PHONPADITH**  
CEO  
SOAR Community  
Network



**MICHAEL RIEMER**  
CEO & Board Member  
Vocinity

# SPONSORS



# WANT TO PRESENT OR SPONSOR AT OUR VIRTUAL EVENTS?

Email Skylar Rallison at  
[srallison@opus8.com](mailto:srallison@opus8.com)  
for more information

## 2025 Virtual Calendar

June 26	July 31
Aug 28	Sept 25
	Oct 30



# CONNECT WITH US!



# REGISTER FOR OUR UPCOMING EVENTS

## In-Person Event

June 12, 2025  
Tysons, VA



## Life Sciences Investor Reception

June 16, 2025  
Boston, MA



## Virtual Event

June 26, 2025  
Online via Zoom



View the  
RSVPs Here

